GALAPAGOS NV-SPON ADR (GLPG) Stock Fundamental Analysis
USA - NASDAQ:GLPG - US36315X1019 - ADR
30.42 USD
-0.34 (-1.11%)
30.42 USD
0 (0%)
Overall GLPG gets a fundamental rating of 2 out of 10. We evaluated GLPG against 533 industry peers in the Biotechnology industry. The financial health of GLPG is average, but there are quite some concerns on its profitability. GLPG is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year GLPG was profitable.
GLPG had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: GLPG reported negative net income in multiple years.
GLPG had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -12.41%, GLPG belongs to the top of the industry, outperforming 83.11% of the companies in the same industry.
With an excellent Return On Equity value of -17.82%, GLPG belongs to the best of the industry, outperforming 85.55% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -12.41% | ||
| ROE | -17.82% | ||
| ROIC | N/A |
ROA(3y)0.68%
ROA(5y)-1.06%
ROE(3y)0.5%
ROE(5y)-2.77%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
In the last couple of years the Profit Margin of GLPG has grown nicely.
Looking at the Gross Margin, with a value of 84.25%, GLPG belongs to the top of the industry, outperforming 86.87% of the companies in the same industry.
GLPG's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for GLPG so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 84.25% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y9.68%
GM growth 3Y-4.31%
GM growth 5YN/A
2. Health
2.1 Basic Checks
GLPG does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for GLPG remains at a similar level compared to 1 year ago.
The number of shares outstanding for GLPG has been increased compared to 5 years ago.
GLPG has a worse debt/assets ratio than last year.
2.2 Solvency
GLPG has an Altman-Z score of 1.49. This is a bad value and indicates that GLPG is not financially healthy and even has some risk of bankruptcy.
GLPG has a better Altman-Z score (1.49) than 65.29% of its industry peers.
GLPG has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
GLPG has a Debt to Equity ratio (0.00) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.49 |
ROIC/WACCN/A
WACC7.88%
2.3 Liquidity
A Current Ratio of 8.62 indicates that GLPG has no problem at all paying its short term obligations.
GLPG has a better Current ratio (8.62) than 76.36% of its industry peers.
A Quick Ratio of 8.55 indicates that GLPG has no problem at all paying its short term obligations.
With a decent Quick ratio value of 8.55, GLPG is doing good in the industry, outperforming 76.36% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.62 | ||
| Quick Ratio | 8.55 |
3. Growth
3.1 Past
The earnings per share for GLPG have decreased strongly by -65.54% in the last year.
GLPG shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -12.47% yearly.
GLPG shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -43.08%.
Measured over the past years, GLPG shows a very negative growth in Revenue. The Revenue has been decreasing by -20.82% on average per year.
EPS 1Y (TTM)-65.54%
EPS 3YN/A
EPS 5Y-12.47%
EPS Q2Q%-308%
Revenue 1Y (TTM)-43.08%
Revenue growth 3Y-20.01%
Revenue growth 5Y-20.82%
Sales Q2Q%18.63%
3.2 Future
The Earnings Per Share is expected to decrease by -40.75% on average over the next years. This is quite bad
GLPG is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -1.29% yearly.
EPS Next Y-346.2%
EPS Next 2Y-95.96%
EPS Next 3Y-65.78%
EPS Next 5Y-40.75%
Revenue Next Year-5.39%
Revenue Next 2Y-2.52%
Revenue Next 3Y-3.52%
Revenue Next 5Y-1.29%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 23.40, which indicates a rather expensive current valuation of GLPG.
Based on the Price/Earnings ratio, GLPG is valued cheaply inside the industry as 93.81% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 25.51. GLPG is around the same levels.
The Forward Price/Earnings Ratio is negative for GLPG. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.4 | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
GLPG's earnings are expected to decrease with -65.78% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-95.96%
EPS Next 3Y-65.78%
5. Dividend
5.1 Amount
GLPG does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
30.42
-0.34 (-1.11%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners25.23%
Inst Owner Change-0.7%
Ins Owners0%
Ins Owner ChangeN/A
Market Cap2.00B
Revenue(TTM)286.76M
Net Income(TTM)-436.00M
Analysts48.24
Price Target34.66 (13.94%)
Short Float %3.41%
Short Ratio8.27
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-6.67%
Min Revenue beat(2)-10.27%
Max Revenue beat(2)-3.08%
Revenue beat(4)1
Avg Revenue beat(4)-5.2%
Min Revenue beat(4)-11.82%
Max Revenue beat(4)4.35%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.51%
PT rev (3m)0.24%
EPS NQ rev (1m)-0.07%
EPS NQ rev (3m)-0.07%
EPS NY rev (1m)0.07%
EPS NY rev (3m)-150.1%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.23%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.4 | ||
| Fwd PE | N/A | ||
| P/S | 6.03 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.71 | ||
| P/tB | 0.71 | ||
| EV/EBITDA | N/A |
EPS(TTM)1.3
EY4.27%
EPS(NY)-2.39
Fwd EYN/A
FCF(TTM)-5.05
FCFYN/A
OCF(TTM)-4.73
OCFYN/A
SpS5.04
BVpS43.05
TBVpS42.92
PEG (NY)N/A
PEG (5Y)N/A
Graham Number35.49
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -12.41% | ||
| ROE | -17.82% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 84.25% | ||
| FCFM | N/A |
ROA(3y)0.68%
ROA(5y)-1.06%
ROE(3y)0.5%
ROE(5y)-2.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y9.68%
GM growth 3Y-4.31%
GM growth 5YN/A
F-Score2
Asset Turnover0.08
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 40% | ||
| Cap/Sales | 6.28% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 8.62 | ||
| Quick Ratio | 8.55 | ||
| Altman-Z | 1.49 |
F-Score2
WACC7.88%
ROIC/WACCN/A
Cap/Depr(3y)93.92%
Cap/Depr(5y)187.53%
Cap/Sales(3y)17%
Cap/Sales(5y)15.79%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-65.54%
EPS 3YN/A
EPS 5Y-12.47%
EPS Q2Q%-308%
EPS Next Y-346.2%
EPS Next 2Y-95.96%
EPS Next 3Y-65.78%
EPS Next 5Y-40.75%
Revenue 1Y (TTM)-43.08%
Revenue growth 3Y-20.01%
Revenue growth 5Y-20.82%
Sales Q2Q%18.63%
Revenue Next Year-5.39%
Revenue Next 2Y-2.52%
Revenue Next 3Y-3.52%
Revenue Next 5Y-1.29%
EBIT growth 1Y-67.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-29.52%
EBIT Next 3Y-12.01%
EBIT Next 5Y14.7%
FCF growth 1Y46.66%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y48.17%
OCF growth 3YN/A
OCF growth 5YN/A
GALAPAGOS NV-SPON ADR / GLPG FAQ
What is the fundamental rating for GLPG stock?
ChartMill assigns a fundamental rating of 2 / 10 to GLPG.
What is the valuation status of GALAPAGOS NV-SPON ADR (GLPG) stock?
ChartMill assigns a valuation rating of 1 / 10 to GALAPAGOS NV-SPON ADR (GLPG). This can be considered as Overvalued.
What is the profitability of GLPG stock?
GALAPAGOS NV-SPON ADR (GLPG) has a profitability rating of 3 / 10.
What are the PE and PB ratios of GALAPAGOS NV-SPON ADR (GLPG) stock?
The Price/Earnings (PE) ratio for GALAPAGOS NV-SPON ADR (GLPG) is 23.4 and the Price/Book (PB) ratio is 0.71.
Can you provide the financial health for GLPG stock?
The financial health rating of GALAPAGOS NV-SPON ADR (GLPG) is 4 / 10.